Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Shortly after posting our last blog on tacicepts, new data was published in the NEJM on the pivotal Phase 3 trial of atacicept. This publication by Lafayette et al. provides results from an IA of the ongoing ORIGIN-3 trial.[1] We updated our table with this new information that centers on Continue reading COMPARISON OF BAFF / APRIL INHIBITORS – 2
First, a reminder where the name ‘Berger’s disease’ or Morbus Berger comes from. It was Jean Berger, a French pathologist and doctor, who initially identified IgA deposits on the glomeruli of nephritic patients. This was not so long ago; his publication (in French) dates from 1968.[1] Now the race is heating Continue reading COMPARISON OF BAFF / APRIL INHIBITORS
In today’s blog we will share our thoughts about a recent NEJM article, entitled “A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus”.[1] Publications on SLE literally come with a book of abbreviations and definitions nowadays and are not an easy Sunday reads. Of course, there is extensive literature Continue reading TELITACICEPT IN SLE